Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotech, Janssen Ink Dx Collaboration

NEW YORK (GenomeWeb) – Adaptive Biotechnologies said today that it has agreed to use its technology to measure the efficacy of Janssen's Darzalex (daratumumab) in multiple myeloma (MM).

Under the terms of the collaboration, Adaptive will use its NGS-based ClonoSeq assay to measure minimal residual disease (MRD) in MM patients treated with Darzalex in ongoing clinical trials. The two companies hope to demonstrate the clinical utility of monitoring MRD as a way of assessing the medication's effectiveness.

Adaptive will receive an undisclosed upfront technology access payment in addition to development funding and potential future milestone payments from its new partner. The company will also be responsible for its own commercialization costs, and for seeking regulatory approval of ClonoSeq.

Adaptive launched ClonoSeq in 2013 as a laboratory-developed test and has said that it does intend to seek clearance from the US Food and Drug Administration for the assay.

The company has also recently announced other pharma collaborations, including an agreement with Amgen to use ClonoSeq to assess MRD in patients with acute lymphoblastic leukemia, and another deal with immuno-oncology firm Argos Therapeutics to study patient response to the firm's investigational immunotherapies.